Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 6/20 | 0.81 |
| ▸ | RET | P07949 | 3/20 | 0.81 |
| ▸ | LCK | P06239 | 5/20 | 0.79 |
| ▸ | SRC | P12931 | 1/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.69 |
| ▸ | FLT1 | P17948 | 1/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | STK10 | O94804 | 1/20 | 0.69 |
| ▸ | FLT3 | P36888 | 1/20 | 0.69 |
| ▸ | JAK3 | P52333 | 1/20 | 0.69 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.69 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.69 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.69 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.69 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.69 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385451 | 1.00 | EGFR (1.00) | EGFRRIPK2EPHB2KDRRET | |
| Hydrochloric Acid SCHEMBL8807925 | 0.99 | EGFR (0.98) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL21442463 | 0.92 | EGFR (0.84) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL15390777 | 0.91 | EGFR (0.83) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL18158215 | 0.90 | EGFR (0.82) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL1387182 | 0.90 | EGFR (0.94) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL29515328 | 0.90 | EGFR (1.00) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL1257431 | 0.90 | EGFR (1.00) | EGFRRIPK2EPHB2KDRRET | |
| Hydrochloric Acid SCHEMBL8811926 | 0.89 | EGFR (0.80) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL8933814 | 0.89 | KDR (0.88) | EGFRRIPK2EPHB2KDRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752150-B2 | Anti-tumor immunotherapy enhancer | NOBUO TSUKAMOTO (JP) | 2023-09-12 | — | — | US | claimed |
| US-20200383981-A1 | Anti-Tumor Immunotherapy Enhancer | KEIO UNIVERSITY (JP) | 2020-12-10 | — | — | US | claimed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| EP-2600150-B1 | Method for determining sensitivity of tumor cells to dasatinib and computer program | SYSMEX CORP (JP) | 2015-01-07 | — | — | EP | claimed |
| US-20130143236-A1 | METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO DASATINIB AND COMPUTER PROGRAM | SYSMEX CORPORATION (JP) | 2013-06-06 | — | — | US | claimed |
| EP-2600150-A2 | Method for determining sensitivity of tumor cells to dasatinib and computer program | Sysmex Corporation (JP) | 2013-06-05 | — | — | EP | claimed |
| EP-2400033-B1 | Method for determining sensitivity of tumor cells to tyrosine kinase inhibitor and computer program product | SYSMEX CORP (JP) | 2013-02-20 | — | — | EP | claimed |
| US-20110318768-A1 | METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO TYROSINE KINASE INHIBITOR AND COMPUTER PROGRAM PRODUCT | SYSMEX CORPORATION (JP) | 2011-12-29 | — | — | US | claimed |
| EP-2400033-A1 | Method for determining sensitivity of tumor cells to tyrosine kinase inhibitor and computer program product | SYSMEX CORPORATION (JP) | 2011-12-28 | — | — | EP | claimed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | claimed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | claimed |
| JP-H10505600-A | — | — | 1998-06-02 | — | — | JP | claimed |
| EP-0782570-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-07-09 | — | — | EP | claimed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | claimed |
| WO-2025261943-A1 | ANTI-CANCER COMBINATIONS COMPRISING MOSPERAFENIB AND FOLFOX OR FOLFIRI | F. HOFFMANN-LA ROCHE AG (CH) | 2025-12-26 | — | — | WO | disclosed |
| EP-4634172-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | F. Hoffmann-La Roche AG (CH) | 2025-10-22 | — | — | EP | disclosed |
| WO-2004001384-A2 | METHODS FOR INHIBITING ANGIOGENESIS, CELL MIGRATION, CELL ADHESION, AND CELL SURVIVAL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-0782570-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | EGFR 411/4885RIPK2 2901/4885EPHB2 2830/4885 |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | EGFR 411/4885RIPK2 2901/4885EPHB2 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.